ALTIMMUNE INC (ALT) Stock News
NASDAQ:ALT - Nasdaq - US02155H2004 - Common Stock - Currency: USD
ALT Latest News, Press Relases and Analysis
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions
GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel...
Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Altimmune, Inc. (NASDAQ:ALT) was one of the stocks that was covered in that article. Wall Street analysts believe ALT has a 288% upside potential over the next 12 months. Altimmune, Inc.(NASDAQ:ALT) is a clinical-stage biopharmaceutical company. It focuses on developing treatments for […]
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel...
Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension
Stock futures are mixed, signaling a potential pause following Monday’s rally driven by optimism over a temporary U.S.-China trade deal. In corporate news, UnitedHealth Group shares plunged 10% after CEO Andrew Witty stepped down, with former CEO Stephen Hemsley stepping in. The company also suspended its outlook due to rising medical costs. Bitcoin has regained value above $103,800, aligning with Coinbase’s rise after inclusion into the S&P 500. In pre-market trading, S&P 500 futures were fla
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel...
Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased
In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH).
Altimmune Announces First Quarter 2025 Financial Results and Business Update
Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in...
Will Healthy Y/Y Revenue Growth Boost Keysight's Q2 Earnings?
KEYS is expected to report year-over-year revenue growth in the second quarter of fiscal 2025, driven by healthy demand across both segments.
Doximity Q4 Earnings Likely to Reflect Strong Product Momentum
Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth.
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86%
The mean of analysts' price targets for Altimmune (ALT) points to a 285.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™
MASH Resolution Index (MASHResInd) model highly predictive of MASH resolution...
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that...
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025
GAITHERSBURG, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing...
Altimmune to Participate in the Citizens Life Sciences Conference
GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced...
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
Here's why they think Altimmune (NASDAQ: ALT), Moderna (NASDAQ: MRNA), and Pfizer (NYSE: PFE) are dirt cheap now, and why buying these value stocks could be a brilliant move. David Jagielski (Altimmune): If you want to swing for the fences, one underrated GLP-1 weight loss drug company you'll want to consider investing in right now is Altimmune. It's not the safest healthcare stock to own as there's no guarantee of how well its GLP-1 drug candidate, pemvidutide, will perform in late-stage trials, but its clinical results so far have been promising.
Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon
A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.
Altimmune to Host Virtual R&D Day on March 13, 2025
Program to Feature Presentations from Renowned KOLs in Obesity, MASH and Two Additional Indications for Pemvidutide following recent IND Clearances by FDA...